Pamela L Wolters1, Staci Martin2, Vanessa L Merker2, James H Tonsgard2, Sondra E Solomon2, Andrea Baldwin2, Amanda L Bergner2, Karin Walsh2, Heather L Thompson2, Kathy L Gardner2, Cynthia M Hingtgen2, Elizabeth Schorry2, William N Dudley2, Barbara Franklin2. 1. From the Pediatric Oncology Branch (P.L.W., S.M., A.B.), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Neurology and Cancer Center (V.L.M.), Massachusetts General Hospital, Boston; University of Chicago Pritzker School of Medicine (J.H.T.), IL; Department of Psychological Sciences (S.E.S.), University of Vermont, Burlington; Departments of Neurology and Genetics (A.L.B.), Johns Hopkins University, Baltimore, MD; Children's National Health System & The George Washington School of Medicine (K.W.), Washington, DC; Department of Speech Pathology & Audiology (H.L.T.), California State University, Sacramento; Veteran's Administration Pittsburgh Healthcare System and University of Pittsburgh (K.L.G.), PA; Department of Clinical Neurosciences (C.M.H.), Spectrum Health Medical Group and College of Human Medicine, Michigan State University, East Lansing; Division of Human Genetics (E.S.), Cincinnati Children's Hospital, OH; Department of Public Health Education (W.N.D.), School of Health and Human Sciences, University of North Carolina at Greensboro; and Advocure NF2 Inc. (B.F.), Los Angeles, CA. woltersp@mail.nih.gov. 2. From the Pediatric Oncology Branch (P.L.W., S.M., A.B.), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Neurology and Cancer Center (V.L.M.), Massachusetts General Hospital, Boston; University of Chicago Pritzker School of Medicine (J.H.T.), IL; Department of Psychological Sciences (S.E.S.), University of Vermont, Burlington; Departments of Neurology and Genetics (A.L.B.), Johns Hopkins University, Baltimore, MD; Children's National Health System & The George Washington School of Medicine (K.W.), Washington, DC; Department of Speech Pathology & Audiology (H.L.T.), California State University, Sacramento; Veteran's Administration Pittsburgh Healthcare System and University of Pittsburgh (K.L.G.), PA; Department of Clinical Neurosciences (C.M.H.), Spectrum Health Medical Group and College of Human Medicine, Michigan State University, East Lansing; Division of Human Genetics (E.S.), Cincinnati Children's Hospital, OH; Department of Public Health Education (W.N.D.), School of Health and Human Sciences, University of North Carolina at Greensboro; and Advocure NF2 Inc. (B.F.), Los Angeles, CA.
Abstract
OBJECTIVE: Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning should be included as study endpoints. Currently, there is no consensus on the selection and use of such measures in the NF population. This article presents the recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and physical functioning for NF clinical trials. METHODS: The REiNS PRO group reviewed and rated existing PRO measures assessing pain intensity, pain interference, and physical functioning using their systematic method. Final recommendations are based primarily on 4 main criteria: patient characteristics, item content, psychometric properties, and feasibility for clinical trials. RESULTS: The REiNS PRO group chose the Numeric Rating Scale-11 (≥8 years) to assess pain intensity, the Pain Interference Index (6-24 years) and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale (≥18 years) to evaluate pain interference, and the PROMIS Physical Functioning Scale to measure upper extremity function and mobility (≥5 years) for NF clinical trials. CONCLUSIONS: The REiNS Collaboration currently recommends these PRO measures to assess the domains of pain and physical functioning for NF clinical trials; however, further research is needed to evaluate their use in individuals with NF. A final consensus recommendation for the pain interference measure will be disseminated in a future publication based on findings from additional published research.
OBJECTIVE:Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning should be included as study endpoints. Currently, there is no consensus on the selection and use of such measures in the NF population. This article presents the recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and physical functioning for NF clinical trials. METHODS: The REiNS PRO group reviewed and rated existing PRO measures assessing pain intensity, pain interference, and physical functioning using their systematic method. Final recommendations are based primarily on 4 main criteria: patient characteristics, item content, psychometric properties, and feasibility for clinical trials. RESULTS: The REiNS PRO group chose the Numeric Rating Scale-11 (≥8 years) to assess pain intensity, the Pain Interference Index (6-24 years) and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale (≥18 years) to evaluate pain interference, and the PROMIS Physical Functioning Scale to measure upper extremity function and mobility (≥5 years) for NF clinical trials. CONCLUSIONS: The REiNS Collaboration currently recommends these PRO measures to assess the domains of pain and physical functioning for NF clinical trials; however, further research is needed to evaluate their use in individuals with NF. A final consensus recommendation for the pain interference measure will be disseminated in a future publication based on findings from additional published research.
Authors: Esi Morgan DeWitt; Brian D Stucky; David Thissen; Debra E Irwin; Michelle Langer; James W Varni; Jin-Shei Lai; Karin B Yeatts; Darren A Dewalt Journal: J Clin Epidemiol Date: 2011-02-02 Impact factor: 6.437
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: Matthias Rose; Jakob B Bjorner; Barbara Gandek; Bonnie Bruce; James F Fries; John E Ware Journal: J Clin Epidemiol Date: 2014-05 Impact factor: 6.437
Authors: Pamela L Wolters; Staci Martin; Vanessa L Merker; Kathy L Gardner; Cynthia M Hingtgen; James H Tonsgard; Elizabeth K Schorry; Andrea Baldwin Journal: Neurology Date: 2013-11-19 Impact factor: 9.910
Authors: Alanna M Kongkriangkai; Christopher King; Lisa J Martin; Emily Wakefield; Carlos E Prada; Geraldine Kelly-Mancuso; Elizabeth K Schorry Journal: Am J Med Genet A Date: 2019-02-08 Impact factor: 2.802
Authors: Mojtaba Talaei-Khoei; Eric Riklin; Vanessa L Merker; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu Journal: J Neurooncol Date: 2016-11-29 Impact factor: 4.130
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Frank D Buono; Matthew E Sprong; Erina Paul; Staci Martin; Kaitlyn Larkin; Amir Garakani Journal: Orphanet J Rare Dis Date: 2021-05-21 Impact factor: 4.123
Authors: Brian D Weiss; Pamela L Wolters; Scott R Plotkin; Brigitte C Widemann; James H Tonsgard; Jaishri Blakeley; Jeffrey C Allen; Elizabeth Schorry; Bruce Korf; Nathan J Robison; Stewart Goldman; Alexander A Vinks; Chie Emoto; Tsuyoshi Fukuda; Coretta T Robinson; Gary Cutter; Lloyd Edwards; Eva Dombi; Nancy Ratner; Roger Packer; Michael J Fisher Journal: J Clin Oncol Date: 2021-01-28 Impact factor: 44.544
Authors: Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling Journal: Neurology Date: 2021-07-06 Impact factor: 11.800
Authors: Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve Journal: Neurology Date: 2021-07-06 Impact factor: 11.800
Authors: Anusha Amaravathi; Janet L Oblinger; D Bradley Welling; A Douglas Kinghorn; Long-Sheng Chang Journal: Front Oncol Date: 2021-09-17 Impact factor: 6.244